Suppliers / Bayer S/A

Bayer S/A

United Arab Emirates 3 duplicate records merged Updated 9 July 2026

Bayer S/A is an API and finished-dose manufacturer based in United Arab Emirates. It holds 26 active US drug master files across a filed portfolio of 20 molecules. Its filings concentrate with ANVISA (Brazil), Health Canada and EMA. Its GMP standing is certified by BPOM (ID), ZLG (DE) and COFEPRIS (MX), among 11 authorities. Its most recent recorded inspection, by US FDA, closed on 20 July 2023 as VAI.

26
active US DMFs
0
valid CEPs
12
registered plants
4,668
filings across 46 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
0 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 20 July 2023 VAI US FDA
  • 17 June 2022 VAI US FDA
  • 9 July 2019 VAI US FDA
  • 19 April 2019 VAI US FDA
  • 17 June 2016 NAI US FDA
  • 16 October 2015 NAI US FDA
  • 20 June 2014 VAI US FDA
  • 15 March 2013 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Berlin, United Arab Emirates Not on file
Leverkusen, United Arab Emirates Not on file
Garbagnate Milanese, United Arab Emirates Not on file
Turku, United Arab Emirates Not on file
Casablanca, United Arab Emirates Not on file
BUENOS AIRES, Argentina Not on file

6 further sites are on record.

Filings and GMP by regulator

Regulator Filings GMP certificates
ANVISA (Brazil) 424 5
Health Canada 419 None
EMA 364 7
INHRR (VE) 341 None
MHRA (UK) 291 2
AIFA (IT) 269 None
BPOM (ID) None 12
ZLG (DE) None 10
COFEPRIS (MX) None 8
HSA (SG) None 4
TMDA (TZ) None 4
MFDS (Korea) None 4
NAFDAC (NG) None 2
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Bayer S/A comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 14 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 20 July 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates